Almirall SA is a global biopharmaceutical company, which is focused on skin health. The company is headquartered in Barcelona, Barcelona and currently employs 2,026 full-time employees. The company went IPO on 2007-04-19. The firm focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The firm's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The firm operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
How did LBTSF's recent EPS compare to expectations?
The most recent EPS for Almirall SA is $0.03, not beating expectations of $0.03.
How did Almirall SA LBTSF's revenue perform in the last quarter?
Almirall SA revenue for the last quarter is $0.03
What is the revenue estimate for Almirall SA?
According to of Wall street analyst, the revenue estimate of Almirall SA range from $ to $
What's the earning quality score for Almirall SA?
Almirall SA has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Almirall SA report earnings?
Almirall SA next earnings report is expected in 2026-05-24
What are Almirall SA's expected earnings?
Almirall SA expected earnings is $286.75M, according to wall-street analysts.
Did Almirall SA beat earnings expectations?
Almirall SA recent earnings of $282.48M does not beat expectations.